A totally implantable system for providing access to the peritoneal cavity was evaluated. Fifty-six Port-A-Cath (Pharmacia Nu Tech, Piscataway, NJ) peritoneal access systems were implanted in 54 cancer patients receiving intraperitoneal chemotherapy. The catheters are accessed by transcutaneous placement of a Huber point needle through a silicone septum at the top of the portal. A total of 32 patient years of experience are reported. The Port-A-Caths have been in place for a median of 22 weeks (range, one to 85). A total of 401 entries have been made for paracentesis, chemotherapy administration, antibiotic administration, peritoneal lavage for cytology, and catheter flushing. There have been six episodes of peritonitis (five Staphylococcus epidermidis, one S aureus) in three patients. There have been no mechanical failures of the Port-A-Caths. Loss of bidirectional flow through the catheter due to fibrin deposition about the catheter has been the major cause of catheter failure. Patient acceptance of the Port-A-Cath has been excellent.
[1]
R. Olshen,et al.
Intraperitoneal cisplatin with systemic thiosulfate protection.
,
1982,
Annals of internal medicine.
[2]
P. Sugarbaker,et al.
Technical considerations in the use of intraperitoneal chemotherapy administered by Tenckhoff catheter.
,
1982,
Surgery, gynecology & obstetrics.
[3]
S. Howell,et al.
Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions.
,
1981,
The Journal of clinical investigation.
[4]
V. Devita,et al.
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
,
1978,
Cancer treatment reports.